Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting

Abstract

Objectives: Since May 2015, adult patients with schizophrenia adequately treated with once monthly paliperidone palmitate (PP1M) may be transitioned to once-every-three-months paliperidone palmitate (PP3M). This study aims to describe baseline characteristics and treatment patterns of patients with schizophrenia initiated on PP3M in a real-world setting.

Methods: Pharmacy and medical claims from May 2014 to September 2016 for adult patients with schizophrenia initiated on PP3M (index date) in the Symphony Health Solutions database were analyzed. The cohort consisting of all patients and the one restricted to those transitioning from PP1M as per prescribing guideline recommendations were considered. Baseline characteristics were assessed during the 12 month baseline period. PP1M treatment patterns, proportion of days covered (PDC) by mental-health-related medications, and healthcare resource utilization (HRU) patterns were evaluated for each baseline quarter. PP3M treatment patterns were assessed post-index.

Results: Among the 1545 adult patients initiated on PP3M who formed the first cohort, 68.8% transitioned from PP1M based on prescribing guidelines and on an adaptation of the strict clinical trial protocol for PP1M to PP3M transition, forming the second cohort. In both cohorts, the proportion of patients with a PDC ≥80% for antipsychotics, antidepressants, anxiolytics, and mood stabilizers increased while the proportion of patients with ≥1 emergency room, inpatient, or outpatient visit decreased in baseline quarters closer to PP3M initiation. Among patients with ≥4 months of follow-up after the first dose, 85–88% had a second dose. Similarly, among those with ≥4 months of follow-up after the second dose, 87–90% received a third dose.

Conclusions: Patients initiated on PP3M demonstrated decreased HRU and increased adherence in quarters closer to PP3M initiation, and were persistent on their PP3M treatment.

Keywords:

• Paliperidone palmitate
• schizophrenia
• adherence
• healthcare resource utilization
• treatment patterns

Transparency

Declaration of funding

This research was funded by Janssen Scientific Affairs LLC.

Declaration of financial/other relationships

K.J., B.B. and N.T. have disclosed that they are employees of Janssen Scientific Affairs LLC and Johnson & Johnson. M.-H.L., W.W., B.E. and P.L. have disclosed that they are employees of Analysis Group Inc., a consulting company that has received research funds from Janssen Scientific Affairs LLC.

CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no relevant financial or other relationships to disclose.

Janssen Scientific Affairs, LLC

Acknowledgment

No assistance in the preparation of this article is to be declared. Part of the material in this manuscript has been presented at the 29th Annual US Psychiatric and Mental Health Congress (October 21-24, 2016, San Antonio, TX) and at the 2017 American Psychiatric Association Annual Meeting (May 20-24, 2017, San Diego, CA).